Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 5/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 13/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 13/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL571792 | 0.86 | CHEK2 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL571791 | 0.86 | CHEK2 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL1293347 | 0.81 | HCRTR1 (0.64) | HCRTR1HCRTR2 | |
| SCHEMBL19385344 | 0.79 | USP30 (0.66) | PRCPHCRTR1HCRTR2 | |
| SCHEMBL19385343 | 0.79 | USP30 (0.66) | PRCPHCRTR1HCRTR2 | |
| SCHEMBL750105 | 0.78 | HCRTR1 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL2512532 | 0.78 | HTR2B (0.50) | PRCPHCRTR1HCRTR2 | |
| SCHEMBL2276747 | 0.78 | BCHE (0.41) | HCRTR1HCRTR2 | |
| SCHEMBL2280366 | 0.76 | CHEK2 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL2280362 | 0.76 | CHEK2 (0.51) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-2318376-B1 | BI-1H-BENZIMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-07-29 | — | — | EP | disclosed |
| US-8809548-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140205564-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-07-24 | — | — | US | disclosed |
| EP-2601188-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-06-12 | — | — | EP | disclosed |
| US-8394968-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2398794-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2012018325-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-11 | — | — | US | disclosed |
| US-7906655-B2 | 5,5'-(1,2-ethynediyl)bis(2-((2S)-1-((2R)-2-phenylpropanoyl)-2-pyrrolidinyl)-1H-benzimidazole); inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | PRCP 190/4885HCRTR1 4453/4885HCRTR2 4639/4885 |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PRCP 190/4885HCRTR1 4453/4885HCRTR2 4639/4885 |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PRCP 190/4885HCRTR1 4453/4885HCRTR2 4639/4885 |
| US-20140205564-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PRCP 190/4885HCRTR1 4453/4885HCRTR2 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.